⚡ Quick Start — If You Read Nothing Else

The 8 most important things to know right now.

Get care at a high-volume pancreatic center immediately. Hospitals that perform many pancreatic surgeries have significantly better outcomes — this single decision can change your prognosis.
Resectability assessment is the first critical question. Whether the tumor can be surgically removed determines your entire treatment path — get this evaluated by an experienced team.
FOLFIRINOX or gem/nab-paclitaxel are the frontline regimens. These combination chemotherapy protocols are the current standard and have meaningfully improved survival rates.
Neoadjuvant chemo before surgery is increasingly standard. Treating with chemotherapy first can shrink the tumor, test its responsiveness, and improve surgical outcomes.
Molecular profiling can unlock targeted options. Testing your tumor for specific mutations (like BRCA, NTRK, or MSI-high) may qualify you for targeted therapies or immunotherapy.
Pain management is a priority from day one. Pancreatic cancer pain is treatable — celiac plexus blocks and proper medication can dramatically improve quality of life.
Clinical trials offer additional options. New therapies are actively being tested, and trials may provide access to treatments not yet widely available.
Palliative care improves outcomes and quality of life. Starting palliative care early alongside treatment helps manage symptoms, nutrition, and emotional wellbeing — it is not about giving up.

▼ Collapse

Understanding Pancreatic Cancer (PDAC)

Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, accounting for roughly 90% of cases. It arises in the cells lining the pancreatic ducts — the tubes that carry digestive enzymes from the pancreas to the intestine. In the United States, roughly 66,000 new cases are diagnosed each year.

Why pancreatic cancer behaves the way it does. A few features explain both the challenges and where the treatment plan comes from. First, the pancreas sits deep in the abdomen, wrapped around major blood vessels and without an outer capsule, so tumors often cause no symptoms until they are sizable or have spread — which is why many are found at a more advanced stage. Second, the tumor surrounds itself with a thick, dense scar-like tissue called the stroma that forms a partial shield, making it harder for chemotherapy to penetrate and for the immune system to attack — this is an active area of research. Third, the location matters for symptoms and treatment: tumors in the head of the pancreas often block the bile duct early (causing jaundice) and may be found somewhat sooner, while tumors in the body or tail tend to stay silent longer. Understanding these features helps make sense of why staging, getting tissue for diagnosis, relieving a blocked bile duct, and starting effective chemotherapy — sometimes before surgery — are all part of the standard sequence.

What “resectable,” “borderline,” and “advanced” mean for you. One of the first and most important things your team determines is whether the tumor can be surgically removed, because this drives the whole plan. Doctors group pancreatic cancer roughly into: resectable (the tumor can likely be removed with surgery), borderline resectable (the tumor touches nearby blood vessels enough that surgery is risky — chemotherapy, often with radiation, is usually given first to shrink it and improve the odds of complete removal), locally advanced (the tumor involves vessels too extensively to remove safely, but has not spread to distant organs — treated mainly with chemotherapy, sometimes radiation, with a chance of becoming operable), and metastatic (the cancer has spread to other organs such as the liver — treated with chemotherapy and supportive care, with the goal of controlling the disease and quality of life). These categories are determined by a specialized scan and reviewed by a multidisciplinary team, and they can change — some tumors that start out borderline or locally advanced become removable after chemotherapy. Knowing which group you are in helps you understand the goals and the reasoning behind each recommendation.

The pancreas sits deep in the abdomen, behind the stomach, and has two distinct jobs. Its exocrine function produces the digestive enzymes that break down food. Its endocrine function produces hormones — including insulin and glucagon — that regulate blood sugar. Pancreatic cancer and its treatment can disrupt both functions, which is why digestion, nutrition, and blood sugar are such important parts of management.

The pancreas has three parts: the head (the widest portion, nestled into the curve of the duodenum), the body (the middle), and the tail (the narrow end, near the spleen). Most pancreatic cancers arise in the head. The location of the tumor determines the type of surgery and the pattern of symptoms.

Several features make PDAC especially challenging:

Late presentation. The pancreas is deep in the body, and early pancreatic cancer usually causes no symptoms. By the time symptoms appear — weight loss, jaundice, new back pain, new diabetes — the cancer has often grown locally or spread.
No effective screening test. Unlike colon or breast cancer, there is no routine screening test for the general population. Surveillance exists only for people at very high inherited risk.
The stroma barrier. Pancreatic tumors build a dense, fibrous shell around themselves (the desmoplastic stroma) that physically blocks drugs from reaching the cancer cells. This is covered in detail below.
Immune evasion. The tumor’s microenvironment actively suppresses the immune system, which is why immunotherapy — transformative in melanoma and lung cancer — has had limited success in most PDAC.

Despite these challenges, meaningful progress is being made. Modern combination chemotherapy has improved survival, universal molecular testing is identifying patients who benefit from targeted drugs, and a new generation of RAS-targeted therapies is showing striking results in trials.

Across all stages, historical five-year survival for pancreatic cancer has been roughly 10–13%. That number is real, and a guide that ignored it would not be trustworthy. But survival statistics describe groups of patients treated in the past — they are not predictions for any individual.

Several factors genuinely tilt the odds:

Patients whose tumor can be surgically removed and who complete modern adjuvant chemotherapy at a specialized center have outcomes substantially better than the all-stage average.
Patients with specific molecular features — a germline BRCA mutation, a mismatch-repair-deficient tumor, a rare targetable fusion — have treatment paths that were not available a decade ago.
The emerging RAS-targeted drugs in advanced trials represent what may be the most important development in this disease in many years.

The honest stance is to hold two things at once: to hope sincerely for the best possible outcome, and to prepare honestly for hard possibilities. These are not opposites.

Early Detection: What Proactive Testing Can Do

Pancreatic cancer is one of the most difficult cancers to detect early, and there is currently no routine screening test recommended for the general population. This honest reality shapes everything below.

Warning signs worth taking seriously. Early pancreatic cancer usually causes no symptoms, which is part of why it is often found late. But certain patterns should prompt prompt medical evaluation, especially in combination or in someone over 50: painless yellowing of the skin or eyes (jaundice), often with dark urine and pale stools, which can signal a tumor blocking the bile duct and warrants urgent assessment; unexplained weight loss and loss of appetite; new upper-abdominal or mid-back pain, classically a deep ache that may be worse lying down or after eating; new diabetes appearing without the usual risk factors, or a sudden worsening of well-controlled diabetes, particularly alongside weight loss; persistent greasy, floating, foul-smelling stools or indigestion; and, less commonly, an unexplained blood clot. None of these symptoms means cancer — they have many ordinary causes — but new or unexplained jaundice, or new diabetes with weight loss in an adult, deserves prompt evaluation rather than waiting.

Who should consider surveillance. While there is no general screening test, people at high inherited risk can benefit from a structured surveillance program (usually annual MRI/MRCP or endoscopic ultrasound at a specialized center). This generally includes those with certain inherited gene changes (such as BRCA2, BRCA1, PALB2, CDKN2A, Lynch syndrome genes, or hereditary pancreatitis genes) combined with a family history, and families with two or more close relatives affected by pancreatic cancer. If pancreatic cancer runs in your family, ask your doctor about genetic counseling — it can clarify whether you qualify for surveillance, which is the one setting where proactive testing can catch the disease earlier, when it is more treatable.

The pancreas sits deep in the body, behind the stomach. Small tumors cause no symptoms and are invisible on standard tests. There is no blood marker sensitive and specific enough for population screening — CA19-9, the most commonly used marker, is not reliable for early detection and is not recommended as a screening tool.

By the time most patients develop symptoms (jaundice, unexplained weight loss, new-onset diabetes after age 50, persistent back pain), the cancer has often advanced beyond what surgery alone can address. Roughly 80% of patients are diagnosed at a stage where surgical removal is no longer straightforward.

While general screening is not recommended, a specific group of people at genuinely elevated risk can benefit from surveillance:

Carriers of inherited mutations in genes such as BRCA1, BRCA2, PALB2, ATM, CDKN2A, or Lynch-syndrome genes, particularly with a family history of pancreatic cancer.
People with a strong family history — multiple relatives with pancreatic cancer, even without an identified mutation.
People with certain hereditary pancreatitis syndromes.

For these high-risk individuals, specialized centers offer annual pancreatic surveillance, typically with MRI with MRCP or endoscopic ultrasound, often beginning around age 50 or earlier if pancreatic cancer struck a family member young. This surveillance has identified early-stage, operable cancers in some patients — a genuine benefit.

The key step: If a patient is found to carry an inherited mutation, first-degree relatives should be offered cascade genetic testing. A relative who tests positive can then be enrolled in a high-risk surveillance program. For Utah and Mountain West families, Huntsman Cancer Institute runs a High-Risk Pancreatic Cancer Clinic for exactly this purpose.

While these symptoms are common and usually have benign causes, the following combination — particularly in someone over 50 — should prompt a conversation with a doctor:

Unexplained weight loss
New-onset diabetes (especially after age 50 with no family history or weight gain to explain it)
Persistent, unexplained abdominal or back pain
Jaundice (yellowing of the skin or eyes)
Unexplained blood clots

New-onset diabetes in an older adult, in particular, can occasionally be an early sign of pancreatic cancer. While the vast majority of new diabetes cases are ordinary Type 2, a physician aware of this association may consider additional evaluation.

For the general population with no known risk factors: there is currently no screening that is recommended or beneficial, and pursuing unnecessary testing can lead to false alarms, invasive follow-up procedures, and anxiety without improving outcomes. The honest answer is that for most people, the worry is not productive.

For people with a known inherited mutation or strong family history: surveillance within a dedicated high-risk program is genuinely worth it. It can detect cancers at an earlier, surgically removable stage. The practical step is to get the patient’s germline genetic test results and, if an inherited mutation is found, ask for a referral to genetic counseling and a high-risk surveillance program for relatives.

Research into better early detection — including blood-based multi-cancer detection tests and improved biomarkers — is active. None has yet reached the point of recommended general screening, but this is one of the most intensely studied areas in pancreatic cancer research.

Staging & Resectability

The single most important fact about a pancreatic cancer is its resectability category — whether the tumor can be surgically removed. This determination shapes the entire treatment plan.

Category	What it means	Typical approach
Resectable	The tumor appears removable with surgery; major blood vessels are clear.	Surgery, usually with chemotherapy before and/or after.
Borderline resectable	The tumor touches or slightly involves nearby vessels; complete removal is uncertain.	Chemotherapy first (neoadjuvant), then surgery if the tumor responds.
Locally advanced	Extensive vascular involvement; surgery cannot safely remove the tumor, but it has not spread to distant organs.	Chemotherapy as the main treatment; radiation in selected cases; surgery rarely possible later.
Metastatic	The cancer has spread to distant organs (most often liver, abdominal lining, or lungs).	Systemic chemotherapy; clinical trials; supportive care.

This assessment requires a pancreas-protocol CT scan — a specialized, contrast-enhanced scan timed to show the tumor’s relationship to the major arteries and veins. A standard CT is not adequate. The scan should ideally be reviewed by a radiologist and surgical team experienced in pancreatic cancer.

The entire treatment plan flows from the resectability determination. Getting it wrong — attempting surgery on a tumor that cannot be fully removed, or declaring a tumor inoperable when an expert center could resect it — can have serious consequences. This is one of the strongest arguments for having the case reviewed at a high-volume pancreatic cancer center before making irreversible decisions.

ðŸ”€ Decision Flowchart: Pancreatic Cancer Initial Assessment

flowchart TD A([Diagnosis Confirmed]) --> B{Resectable} B -->|Yes| C[Consider Neoadjuvant Chemo] C --> D([Surgery]) D --> E([Adjuvant Chemo]) B -->|No| F{Borderline Resectable} F -->|Yes| G[Neoadjuvant Chemo] G --> H{Resectable Now} H -->|Yes| I([Surgery]) H -->|No| J([Continue Chemo]) F -->|No| K{Locally Advanced} K -->|Yes| L[Chemo +/- Radiation] L --> M([Reassess]) K -->|No| N[Metastatic - Systemic Chemo] N --> O([FOLFIRINOX or Gem-NabP]) N --> P([Molecular Profiling])

Simplified overview — actual decisions involve many more factors. Discuss with your medical team.

The Stroma Problem: Why Drugs Struggle to Reach the Tumor

Every cancer has a central obstacle that shapes its treatment. In pancreatic cancer, it is the stroma — the dense, fibrous tissue the tumor builds around and within itself.

A pancreatic tumor is not a simple ball of cancer cells. Often the majority of the tumor’s volume is scar-like connective tissue — packed with fibrous proteins such as collagen, with a thick gel-like substance, and with normal cells that the cancer has recruited and reprogrammed to support it. This is the desmoplastic stroma.

The stroma works against treatment in several ways:

Blocks drug delivery. It squeezes the small blood vessels inside the tumor and raises internal pressure, so only a fraction of a chemotherapy dose physically reaches the cancer cells.
Creates low oxygen. With blood vessels crushed, parts of the tumor become hypoxic, which makes cancer cells more aggressive and resistant to radiation.
Hides the cancer from the immune system. The stroma is rich in signals that suppress immune cells — a major reason immunotherapy has largely disappointed in PDAC.

An obvious idea — dissolving the stroma so drugs can get in — has been tried, and the results were cautionary. Early drugs that aggressively stripped away the stroma actually made outcomes worse. Researchers learned that the stroma, while it blocks drugs, also physically restrains the cancer cells. Modern research aims to carefully modify the stroma rather than destroy it.

This explains why modern treatment relies on intensive multi-drug chemotherapy (overwhelming force) and smarter delivery systems (such as the liposomal irinotecan in NALIRIFOX, designed to exploit the tumor’s leaky vessels).

Evaluating Treatment Claims

Families searching online will encounter long lists of additional therapies — repurposed drugs, high-dose supplements, special diets, metabolic protocols, clinics in other countries. Understanding why most have not been proven can help sort the genuine options from the noise.

Proving a treatment works requires a clinical trial, ideally a large randomized one. Such trials cost tens to hundreds of millions of dollars. The organizations that fund them expect to recover that investment through sales of a patentable drug. That model works poorly for drugs that have been generic for decades and for inexpensive supplements.

So a drug that has been generic for thirty years — even one with laboratory signals against pancreatic cancer cells — rarely gets the definitive trial that would tell us whether it actually helps. This is not a conspiracy; it is the structure of how the system is funded.

Pancreatic cancer carries an extra challenge: because of the dense stroma, it has been a graveyard for drugs that looked promising in the laboratory. Many treatments that work against cancer cells in a dish have failed in pancreatic cancer trials because they could not reach the tumor.

Where does the evidence come from? Peer-reviewed journals (searchable at PubMed: pubmed.ncbi.nlm.nih.gov) are the strongest source. Be especially wary of any website that sells the product it recommends.
Has it been tested in pancreatic cancer specifically, and in people? Laboratory studies in dishes are a very early step. Pancreatic cancer in particular has a long record of laboratory successes that did not survive contact with patients.
What kind of human study? A randomized trial is the gold standard. A case report — one patient who did well — tells you almost nothing.
Does it interfere with standard treatment? Even a safe-seeming supplement can change how the liver processes chemotherapy or raise bleeding risk before surgery.
Does anyone with no financial stake recommend it? If the only promoters are the sellers, treat that as a serious warning sign.
Are the doctors at major pancreatic cancer centers using it? If the specialists at Huntsman, Johns Hopkins, MD Anderson, and similar centers are not using a treatment, there is usually a reason.

A warning worth stating directly. If anyone — a practitioner, a website, a well-meaning acquaintance — tells you that standard treatment is poison or a fraud and that some natural protocol can replace it, that person should not be guiding cancer decisions. Standard care is imperfect, and this guide is honest about that. But it has, by an enormous margin, the strongest evidence of any approach. Build on it. Add to it carefully, with the team’s knowledge. Do not abandon it.

The Phases of Treatment

Knowing the shape of the whole journey helps a family anticipate what is coming and reduces the sense of chaos.

The theme is to find out exactly what the tumor is and where it stands, assemble the team, address anything urgent, and start proven treatment — quickly, but without skipping steps. Key actions include: confirming the tissue diagnosis, completing pancreas-protocol imaging, determining the resectability category, ordering germline and tumor molecular testing, relieving a blocked bile duct if present, beginning nutrition support, and screening for clinical trials.

The theme is to execute the main treatment plan with the highest possible adherence while protecting the patient’s strength, nutrition, and quality of life. For surgical candidates, this phase contains chemotherapy and the operation. For advanced disease, it is first-line chemotherapy with trial enrollment considered. Throughout, supportive care is active: nausea, pain, enzyme replacement, and blood sugar are managed deliberately.

After curative-intent treatment, the theme becomes vigilant surveillance for recurrence — scheduled imaging and CA19-9, usually every three to six months. For advanced disease, this phase may mean maintenance therapy or a planned transition to the next line of treatment. This is the phase in which the family should, while the patient is stable, develop a contingency plan for future decisions.

Standard Treatment Foundation

Standard care for pancreatic cancer is a sequence: accurate staging, multidisciplinary review, a tissue diagnosis, relief of a blocked bile duct if present, chemotherapy, surgery when the tumor can be removed, and meticulous supportive care woven through all of it.

Understanding the chemotherapy options — in plain language. Chemotherapy is central to treatment at almost every stage, and there are a few main combinations your team will choose between based on how fit and strong you are. FOLFIRINOX (usually a gentler “modified” version, mFOLFIRINOX) combines several drugs and is the most intensive option; it tends to work well but has more side effects, so it is used for people who are relatively strong and active. Gemcitabine with nab-paclitaxel (Abraxane) is another strong combination that many people tolerate a bit more easily and is often chosen for those who are somewhat less robust. NALIRIFOX, a newer four-drug combination approved by the FDA in 2024, gives doctors an additional well-studied first-line choice. For people who are frail, gentler single-drug treatment focuses on comfort and control. None of these is universally “best” — the right choice depends on your overall health, other medical conditions, and what matters to you, and your oncologist will explain why a particular regimen fits your situation. It is always reasonable to ask: why this regimen for me, what are the likely side effects, and what is the goal we are aiming for?

A note on timing and second opinions. Pancreatic cancer care moves quickly, and the order of treatments matters. In many cases — especially when the tumor is “borderline” or close to important blood vessels — chemotherapy is given before surgery (called neoadjuvant therapy) to shrink the tumor, treat cancer cells that may have already spread, and make a complete removal more likely. Because these decisions are complex and the difference between centers is real, getting evaluated at a high-volume pancreatic cancer center — and seeking a second opinion — is a wise, normal step, not a sign of distrust in your local team. Many people are co-managed, receiving chemotherapy closer to home while a specialized center guides surgical decisions.

Surgery is the only treatment that can potentially cure pancreatic cancer, and it is available only when the tumor can be completely removed. The type depends on where the tumor sits:

Whipple procedure (pancreaticoduodenectomy). For tumors in the head of the pancreas. Removes the pancreatic head, duodenum, gallbladder, and part of the bile duct. The most common operation.
Distal pancreatectomy. For tumors in the body or tail. Removes the body and tail of the pancreas, usually with the spleen.
Total pancreatectomy. Removal of the entire pancreas. Causes permanent insulin-dependent diabetes and complete exocrine insufficiency.

The volume-outcome relationship for pancreatic surgery is among the strongest in all of medicine. Hospitals and surgeons who perform many pancreatic operations have lower surgical mortality, fewer serious complications, higher rates of complete removal, and better long-term survival. This is one of the strongest arguments for getting to a high-volume center.

Regimen	Components	Typical use
FOLFIRINOX / mFOLFIRINOX	Fluorouracil, leucovorin, irinotecan, oxaliplatin	Before or after surgery in fit patients; first-line advanced disease. The PRODIGE 24 trial showed it roughly doubled median disease-free survival after surgery compared to gemcitabine.
Gemcitabine + nab-paclitaxel	Two drugs	A widely used combination for advanced disease and in perioperative settings; generally better tolerated than FOLFIRINOX.
NALIRIFOX	Liposomal irinotecan, fluorouracil, leucovorin, oxaliplatin	The NAPOLI-3 trial found it improved median survival (about 11.1 vs. 9.2 months) over gem+nab-paclitaxel in metastatic disease. FDA-approved 2024 for first-line metastatic disease.
Gemcitabine alone	Single drug	For frail patients who cannot tolerate combinations; provides symptom relief with fewer side effects.

Multi-drug regimens are more toxic than gemcitabine alone, but they provide longer survival in patients fit enough to receive them. An important finding from NAPOLI-3: patients who needed dose reductions still kept the survival benefit — a reason to report side effects rather than silently endure them.

FOLFIRINOX / mFOLFIRINOX: what to expect side-effect-wise

FOLFIRINOX is one of the most effective regimens but also the most demanding. Common side effects and practical management:

Neutropenia (low white blood cells) — The most common serious toxicity. Your team will check blood counts before each cycle. Growth-factor injections (G-CSF, e.g., Neulasta or Zarxio) are routinely given to reduce infection risk. Modified FOLFIRINOX (mFOLFIRINOX) omits the 5-FU bolus, which significantly reduces neutropenia rates while maintaining efficacy — this is now the standard version used in most centers.
Fatigue — Often cumulative over cycles. Plan lighter activity in the days following infusion. Gentle daily movement (walking) can help more than complete rest.
Diarrhea — Caused primarily by irinotecan. Your team will prescribe loperamide (Imodium) to take at the first sign of loose stools. Severe or persistent diarrhea (>4 episodes/day or lasting >24 hours) warrants a call to your oncology team, as it can cause dangerous dehydration.
Nausea and vomiting — FOLFIRINOX is classified as a highly emetogenic regimen. Standard anti-nausea protocols include a 3-drug combination (a 5-HT3 antagonist such as ondansetron, dexamethasone, and an NK1 antagonist such as aprepitant) given before each infusion, with rescue medications for breakthrough nausea.
Peripheral neuropathy — Tingling, numbness, or cold sensitivity in fingers and toes, caused by oxaliplatin. Report early symptoms promptly — dose reduction or removal of oxaliplatin from the regimen can prevent progression to permanent nerve damage. Avoid cold foods and drinks during and for a few days after infusion.
Mucositis / mouth sores — Caused by fluorouracil. Gentle oral hygiene (soft toothbrush, salt-and-soda rinses) helps. Prescription mouthwashes are available for more severe cases.

Key point: Dose reductions are normal and expected — they are not a sign of failure. Most patients require at least one dose modification during the course of treatment, and clinical trials confirm that dose-reduced regimens still provide meaningful survival benefit.

Neoadjuvant (before surgery) chemotherapy is increasingly used, particularly for borderline resectable tumors. The PREOPANC (NCT01458717) trials established neoadjuvant therapy before surgery for resectable and borderline resectable disease. Benefits include testing the tumor’s biology, treating microscopic spread early, and potentially making a borderline tumor resectable.

Adjuvant (after surgery) chemotherapy aims to destroy microscopic cancer cells remaining after surgery. Modified FOLFIRINOX is the preferred adjuvant regimen for fit patients, based on the PRODIGE 24 trial results.

Radiation has a real but more limited role than chemotherapy in PDAC. Settings where it may be considered include:

As part of neoadjuvant treatment, to help clear margins in borderline resectable disease
In the adjuvant setting for selected situations (positive margin or involved lymph nodes)
For locally advanced unresectable disease that has been controlled with chemotherapy, including SBRT (stereotactic body radiation therapy)
For palliative pain relief, including radiation directed at the celiac nerve plexus

Because the pancreas sits among radiation-sensitive structures, these decisions belong to a radiation oncologist experienced specifically in gastrointestinal cancers.

CA19-9 is a protein that most — though not all — pancreatic cancers shed into the blood. It is the most useful blood marker available but has real limitations:

Pattern	Usual interpretation	What it generally prompts
Falling during treatment	Treatment is likely working	Continue as planned; confirm with imaging.
Stable but elevated	Possibly stable disease	Correlate with imaging; do not change treatment on the marker alone.
Risen on a single measurement	May be a false alarm — stent issue, infection	Repeat in a few weeks; rule out innocent causes.
Persistently rising	Suspicious for progression	Order imaging; reassess the whole plan.
Never elevated despite obvious tumor	Patient is likely Lewis-antigen negative	Rely on imaging and symptoms; marker cannot be used.

Choosing a Treatment Center

Of all the choices made after a pancreatic cancer diagnosis, one of the most important is where care is delivered. The difference between a high-volume specialized center and a general community hospital can be substantial.

Why volume matters — especially for surgery. Pancreatic surgery, particularly the Whipple operation, is one of the most demanding procedures in all of cancer care. Research consistently shows that hospitals and surgeons who perform many of these operations each year have markedly lower complication and death rates — and better long-term survival — than those who do few. This is one of the largest “practice makes a difference” effects in surgery, which is why every major guideline recommends that pancreatic surgery be done at a high-volume center. The benefit is not only the operation itself: specialized centers bring an experienced multidisciplinary team (surgeons, medical and radiation oncologists, gastroenterologists, dietitians, genetic counselors, and palliative-care specialists who focus on this disease), access to clinical trials, and the day-to-day expertise to manage complications quickly when they arise.

What this means in practice — and what recovery involves. Seeking care at, or at least a consultation with, a high-volume pancreatic center is a reasonable and important step even if some of your treatment is then delivered closer to home in a “shared care” arrangement. If you are facing a Whipple or other pancreatic surgery, it helps to know what to expect: it is a major operation with a hospital stay typically of about a week (longer if complications occur) and a recovery measured in weeks to a few months. Eating changes afterward — smaller, more frequent meals, pancreatic enzyme capsules with food, and attention to blood sugar — and a dietitian is central to recovery. Fatigue is normal and improves gradually. Knowing this in advance, and choosing an experienced center, gives you the best chance of a smooth recovery and of moving on to any further treatment in good condition. Ask prospective centers directly how many pancreatic resections they perform per year, and do not hesitate to travel for surgery if a high-volume center is within reach.

High-volume centers have:

Lower surgical mortality and fewer serious complications
Higher rates of complete removal with clear margins
More experience managing intensive chemotherapy side effects without unnecessary dose reductions
A genuine multidisciplinary tumor board
A larger menu of clinical trials
Dedicated supporting services: pancreatic-cancer dietitians, interventional gastroenterologists, genetic counselors, pain and palliative care specialists

A patient does not have to receive every part of their care at such a center. A common arrangement is to have the key decisions — above all the surgical decision — made at a high-volume center, with chemotherapy delivered closer to home in coordination.

A second opinion is most useful when it has a specific job: confirm a complex resectability assessment, and identify clinical trials. A second opinion is standard practice in oncology; major centers expect and coordinate it, and a good home team will help assemble the records. It does not have to delay starting treatment.

How to do it efficiently: Gather the imaging on a disc, pathology slides or report, operative note if any, molecular results, and a treatment summary. Contact the chosen center’s new-patient or second-opinion office. Most major centers can have specialists review the material and provide an opinion by video or in writing without an in-person visit.

The First Weeks: A Concrete Action Checklist

The weeks immediately after a diagnosis are chaotic, frightening, and unfortunately the period when the most time-sensitive decisions must be made.

The handful of things that matter most early. It is easy to feel paralyzed, so it helps to focus on a few high-impact actions. First, get to (or consult with) a high-volume pancreatic cancer center — this single step shapes the quality of every decision that follows, and a second opinion is normal and encouraged. Second, make sure the staging workup is complete and a tissue diagnosis is obtained before any treatment, and that a blocked bile duct, if present, is relieved. Third, ask for germline and tumor genetic testing right away — results take a few weeks and can open doors to targeted treatments, trials, and family screening, so the sooner they are ordered the better. Fourth, start supportive care in parallel, not later: a cancer dietitian (and pancreatic enzymes if you have digestive symptoms), pain control, and a palliative-care referral for quality of life. Fifth, bring a companion to appointments to take notes and help you remember and decide, and keep a single folder (paper or digital) with your records, scans, medication list, and contacts.

Pace yourself and protect your energy. You do not have to understand everything at once, and you do not have to make every decision in the first visit — but a small number of decisions (where to be treated, completing staging, starting genetic testing, relieving jaundice) genuinely are time-sensitive, while others can wait a little. Write down your questions as they come, ask your team what the immediate next step is and what the timeline looks like, and lean on patient-organization helplines (such as PanCAN’s) for free, knowledgeable guidance and trial matching. Taking the illness one clear step at a time — rather than trying to absorb the whole road at once — is both more effective and easier to bear.

When	Action
Right away	Confirm a pancreas-protocol CT (or MRI) has been done and reviewed by a high-volume team.
Right away	Ask the oncologist to order both germline genetic testing and full tumor molecular profiling. Confirm mismatch-repair testing.
Within 48 hours	If the patient is jaundiced, ask about biliary drainage. A self-expanding metal stent is generally preferred over plastic for a long chemotherapy course.
Within 1 week	Ensure a tissue diagnosis has been obtained (usually by endoscopic ultrasound with biopsy). Ask whether extra tissue can be banked.
Within 1 week	Confirm the case is scheduled for multidisciplinary tumor board review.
Within 1 week	Get a baseline CA19-9. If normal despite an obvious tumor, ask about Lewis-antigen status.
Within 1 week	Request a referral to an oncology dietitian. If there is weight loss, bloating, or greasy stools, ask about starting PERT now.
Within 1–2 weeks	Initiate a second opinion at a high-volume center if desired. Remote record review is enough.
Within 2 weeks	Screen for clinical trials — through the treating center, through PanCAN Patient Services (1-877-272-6226).
Within 2 weeks	Meet with a palliative or supportive care team for symptom management (alongside treatment, not instead of it).
Within 2–3 weeks	Complete core legal documents: advance directive, health care power of attorney, financial power of attorney.
Before chemo starts	Dental check (chemo raises infection risk), infusion port placement if needed, anti-nausea prescriptions filled.

Two principles: The treatment clock is real — weeks lost to indecision can close off choices. But speed is not the same as haste — rushing into surgery at a low-volume hospital without proper staging is its own serious mistake. The goal is to move with purpose — deliberate, organized, and fast — not frantic.

If the patient is going to surgery, ask the surgeon explicitly whether a portion of the removed tumor can be snap-frozen, not only preserved in the standard way (formalin/wax). Snap-frozen tissue allows the tumor to be grown as an organoid (a living model for drug testing) and is required for some personalized-vaccine and research trials. Tissue is only available once. Ask early what tissue banking, snap-freezing, organoid generation, and trial-linked collection are available.

Tissue, Biopsies & What Can Be Tested

Endoscopic ultrasound-guided biopsy. The most common source. A thin scope passed through the mouth, from which a fine needle samples the tumor.
Biopsy of a metastasis. A more accessible site (e.g., a liver lesion) is sometimes sampled instead.
Surgical specimen. Provides the most tissue for detailed analysis.

A needle biopsy has two jobs: confirm the diagnosis, and provide enough tissue for full molecular testing. A small sample may confirm adenocarcinoma but be too small for a complete molecular profile. Because molecular testing shapes treatment, make sure from the start that the biopsy obtains adequate tissue.

Liquid biopsy (blood-based testing) can sometimes identify treatable mutations when tissue is limited. It is a valuable complement, though tissue testing remains the reference standard where adequate tissue is available. Whether earlier detection of recurrence by liquid biopsy changes outcomes is still being studied.

The Molecular & Genetic Decision Tree

This section is the heart of modern pancreatic cancer treatment. Testing the patient’s inherited DNA and the tumor’s own DNA can change which chemotherapy is chosen, open targeted drugs and immunotherapy, and unlock clinical trials. National guidelines now recommend this testing for every patient.

Germline genetic testing examines the DNA the patient was born with (blood or saliva). It looks for inherited mutations in genes such as BRCA1, BRCA2, PALB2, and ATM. Roughly 5–10% of patients carry such a mutation. Results take about 2–4 weeks.

Somatic (tumor) molecular profiling examines the DNA of the cancer itself from biopsy or surgical tissue. Using next-generation sequencing, it identifies mutations, amplifications, and gene fusions driving the tumor.

Both should be ordered early. They do not delay standard chemotherapy. PanCAN’s Know Your Tumor program (1-877-272-6226) is one free route to comprehensive profiling.

This is a favorable and actionable result. Two main implications:

Platinum-based chemotherapy is preferred. FOLFIRINOX or NALIRIFOX (both containing the platinum drug oxaliplatin) is generally the chemotherapy of choice when the patient is fit enough.
Olaparib maintenance. For metastatic disease controlled on at least ~16 weeks of platinum-based chemotherapy, olaparib (a PARP inhibitor pill) is an approved maintenance option. The POLO trial (NCT02184195) showed significantly longer progression-free survival (7.4 vs. 3.8 months; hazard ratio 0.53). Roughly a third of olaparib patients were alive at three years, versus under a fifth on placebo.

Only about 1–2% of pancreatic cancers have this feature, but when present it changes treatment substantially. A mismatch-repair-deficient tumor accumulates many mutations, making it visible to the immune system. The immunotherapy drug pembrolizumab has tumor-agnostic FDA approval for any dMMR/MSI-high cancer, and some patients have durable responses.

This is precisely why universal tumor testing matters: the feature is rare, but when present it opens a genuinely meaningful option that would be missed without testing.

More than 85–90% of pancreatic cancers are driven by a KRAS mutation. Long considered “undruggable,” this is now changing:

KRAS G12C inhibitors (sotorasib, adagrasib) have shown activity in the ~1% of pancreatic cancers with this variant.
Pan-RAS inhibitors are the bigger news. Daraxonrasib (RMC-6236), a once-daily pill targeting multiple forms of mutated RAS, showed striking results in the phase 3 RASolute 302 trial in previously treated metastatic disease: roughly doubled median overall survival (~13.2 vs. 6.7 months; hazard ratio 0.40). As of mid-2026, daraxonrasib is still investigational — not yet FDA-approved for routine use. The FDA permitted an expanded-access program in May 2026 for eligible patients. Other trials, including first-line trials, are underway.

What this means now: These results are genuinely promising, but no patient should delay or replace proven chemotherapy to pursue them. The concrete action is to ask: Is there a RAS-targeted clinical trial this patient could join, and does the patient qualify for the daraxonrasib expanded-access program?

About 10% of pancreatic cancers lack a KRAS mutation. These “KRAS wild-type” tumors deserve especially careful molecular examination, as they are enriched for rare but highly treatable alterations:

NTRK fusions — drugs larotrectinib or entrectinib (tumor-agnostic FDA approval); very high response rates.
NRG1 fusions — zenocutuzumab (Bizengri) has FDA accelerated approval for PDAC with NRG1 fusion.
BRAF alterations — potentially treatable with BRAF-targeted combinations.
RET fusions — treatable with selpercatinib (tumor-agnostic approval).
ALK, ROS1, FGFR2, HER2 — each can open a targeted drug or clinical trial.

These are individually rare but collectively meaningful. They will only be found if the tumor is fully profiled — the strongest single argument for universal molecular testing.

International Adjuvant Research

Standard adjuvant chemotherapy after pancreatic cancer surgery varies by region. In the United States and Europe, modified FOLFIRINOX or gemcitabine + capecitabine are the guideline-preferred regimens. In Japan, a different approach has become standard based on a landmark trial.

S-1 is an oral fluoropyrimidine combination (tegafur, gimeracil, and oteracil) that is widely used in East Asian oncology. The JASPAC-01 trial was a Phase 3 randomized controlled trial conducted in Japan that compared adjuvant S-1 to adjuvant gemcitabine in 385 patients who had undergone surgical resection for pancreatic cancer.

Key results:

2-year overall survival: 70% (S-1) vs. 53% (gemcitabine)
Hazard ratio for overall survival: 0.57 (95% CI: 0.44–0.72; p<0.0001 for both non-inferiority and superiority)
S-1 was not only non-inferior but statistically superior to gemcitabine as adjuvant therapy

Published in The Lancet 2016 (PubMed 27265347).

What this means for patients. S-1 is the standard adjuvant therapy in Japan following pancreatic cancer surgery. In Western countries, the standard remains gemcitabine + capecitabine (based on ESPAC-4) or modified FOLFIRINOX (based on PRODIGE 24) for fit patients. The difference partly reflects population pharmacogenomics — the enzyme CYP2A6, which metabolizes a component of S-1, varies in activity between populations, and S-1 dosing in East Asian populations differs from that studied in Western trials. S-1 is not routinely used in the United States for this indication. Ask your oncologist about the relevance of this data to your specific situation.

Nutrition, Digestion, Weight & Blood Sugar

In pancreatic cancer, nutrition and metabolism are not side issues — they are part of the treatment. A patient who maintains weight and strength tolerates chemotherapy better, recovers from surgery faster, and remains eligible for more treatment and for trials.

Enzyme replacement is one of the most important — and most overlooked — treatments. The pancreas makes enzymes that digest food, and pancreatic cancer (or its surgery) often blocks or reduces them. The result is that food passes through without being properly absorbed, causing weight loss, weakness, bloating, gas, and pale, greasy, floating, foul-smelling stools that are hard to flush. This condition has a name — exocrine pancreatic insufficiency — and a straightforward treatment: pancreatic enzyme replacement therapy (PERT), prescription enzyme capsules taken with every meal and snack. Many patients are under-dosed or never started on PERT, and correcting this can dramatically improve energy, weight, and quality of life. Key practical points: take the capsules with food (at the start of and during the meal, not afterward), use smaller amounts with snacks, and tell your team if symptoms persist — the dose often needs to be increased. If you have ongoing greasy stools, bloating, or unexplained weight loss, ask specifically: “Am I on enough pancreatic enzymes?”

Blood sugar, appetite, and practical eating. The pancreas also makes insulin, so new or worsening diabetes is common — sometimes it is even the first sign of the cancer — and blood sugars may need monitoring and treatment, ideally with help from your team or a diabetes specialist. Appetite loss and early fullness are nearly universal; small, frequent, calorie- and protein-dense meals usually work better than three large ones, and a dietitian who specializes in cancer (ideally pancreatic cancer) is one of the most valuable members of your team. Do not wait until significant weight is lost to involve nutrition support — ask for a referral early. When eating by mouth is not enough, options such as oral supplements or, in some cases, tube feeding can help maintain strength. Treating nausea proactively, staying as active as you can, and addressing depression and anxiety (which blunt appetite) all feed back into better nutrition. The recurring theme: nutrition is active treatment, and speaking up early about digestion, weight, and appetite changes outcomes.

Important: The goal in pancreatic cancer is almost always to maintain or gain weight and preserve muscle. This is not a setting for restrictive diets, fasting protocols, or diets that claim to “starve” the cancer. Weight and muscle loss are among the leading threats. All nutrition decisions should be made with an oncology dietitian and the medical team.

When a tumor blocks the pancreatic duct, or surgery removes part of the gland, the body can no longer deliver enough digestive enzymes. The result is EPI — very common in pancreatic cancer.

Signs: Greasy, pale, foul-smelling stools that may float; bloating, cramping, excess gas; continued weight loss despite eating.

Treatment is PERT (pancreatic enzyme replacement therapy) — prescription capsules of digestive enzymes. The major brand names are Creon, Zenpep, Pancreaze, and Viokace; all are FDA-approved prescription products (over-the-counter enzyme supplements are not adequate substitutes). Practical points that make the difference:

Underdosing is the most common error. A typical starting dose is about 40,000–50,000 units of lipase with a main meal and roughly half that with snacks. Patients with severe insufficiency or total pancreatectomy may need 75,000+ units per meal. If symptoms persist, the dose should be increased before concluding the enzymes are not working.
Timing matters. Capsules must be taken with food — the first capsule with the first bites of a meal, and additional capsules spread through the meal if the dose requires more than one.
An acid-reducing medication (PPI) may be added as stomach acid can degrade the enzymes.
PERT can be expensive. Every major manufacturer runs copay assistance programs (e.g., Creon’s CREONConnect, AbbVie’s patient-assistance program). Ask the oncology pharmacist or social worker to help enroll. Most commercial insurance and Medicare Part D cover PERT with prior authorization.

Many patients with pancreatic cancer develop cachexia — progressive weight loss, muscle wasting, and metabolic disruption. It is driven by inflammatory signals from the tumor and cannot be fully reversed by food alone. Several things genuinely help:

Treat it early. Intervening while weight loss is still modest is far more effective than waiting.
Work with an oncology dietitian. This is not optional in pancreatic cancer.
Prioritize protein and calories in small, frequent meals. Medium-chain-triglyceride oil is a calorie source that does not require pancreatic enzymes to absorb.
Ask about low-dose olanzapine. At ~2.5 mg daily, it reduces nausea and meaningfully stimulates appetite. In controlled trials, it improved appetite, nutritional status, and weight.
Keep moving. Light physical activity helps preserve muscle and improves fatigue, mood, and treatment tolerance.
Consider supplemental feeding before crisis. Discuss enteral nutrition proactively rather than waiting for severe wasting.

Pancreatic cancer and its surgery frequently disturb blood sugar. Removing part or all of the pancreas causes or worsens diabetes, and the result is a distinct form called type 3c (pancreatogenic) diabetes.

The key difference: in type 3c, the pancreas loses not only insulin (which lowers blood sugar) but also glucagon (which raises it). Blood sugar becomes “brittle” — prone to wide, rapid swings with a real risk of dangerous hypoglycemia.

If the patient has diabetes or has pancreatic surgery, ask for the involvement of an endocrinologist or diabetes educator. Type 3c diabetes is manageable but managed differently from ordinary diabetes.

Dumping syndrome. After a Whipple, food can move too quickly into the small intestine. Managed by smaller/more frequent meals, limiting concentrated sweets, and separating drinks from solid food.
Delayed gastric emptying. Usually improves with time.
If the spleen was removed. Specific vaccinations are recommended and any fever should be reported promptly.

Supportive Care That Changes Outcomes

Supportive care is not what happens when treatment stops. It is specialized medical care focused on relieving symptoms and stress, delivered alongside cancer treatment from the day of diagnosis. Evidence is consistent: patients who receive early supportive care have better quality of life and, in several studies, have lived as long as or longer than those who did not.

The specific issues to stay ahead of. Several complications are common enough in pancreatic cancer that they should be anticipated rather than waited for. Blocked bile duct (causing jaundice) is often relieved with a small stent placed during an endoscopy, restoring liver function and allowing chemotherapy to proceed. Blocked stomach outlet, causing nausea and vomiting, can sometimes be relieved with a stent or a minor procedure. Blood clots (in the legs or lungs) are notably more common in pancreatic cancer, so report new leg swelling, or sudden shortness of breath or chest pain, immediately — clots are very treatable when caught. Depression and anxiety are common, understandable, and treatable; addressing them improves appetite, energy, and quality of life, so accept help and ask for it. Fatigue responds, perhaps surprisingly, to gentle activity and treating its contributors (anemia, poor nutrition, low mood, poor sleep). Building a team — oncologist, surgeon, a cancer dietitian, a palliative-care clinician, and social-work support — and keeping all of them informed about new symptoms is how these issues get caught early.

Palliative care vs. hospice — an important distinction. Many people avoid the words “palliative care” because they confuse it with hospice or with giving up. They are not the same. Palliative care is symptom- and quality-of-life-focused care given at the same time as active cancer treatment, often for months or years, and asking for it is one of the most evidence-backed things you can do for both how you feel and, in some studies, how long you live. Hospice is a specific kind of comfort-focused care for when cancer-directed treatment is no longer helping and the focus shifts entirely to comfort, usually in the last months of life. Knowing the difference lets you accept the benefits of palliative care early without feeling that you are abandoning treatment — and lets you make hospice decisions, if and when they come, on your own terms and with enough time to choose well.

The single most misunderstood term in cancer care. Palliative care does not mean giving up, and it is not the same as hospice. It is a medical specialty in symptom control — pain, nausea, appetite, fatigue, breathlessness, anxiety — provided at the same time as chemotherapy, surgery, and radiation, at any stage.

Asking for an early palliative care referral is one of the highest-value, lowest-cost things a family can do. It does not replace the oncology team; it strengthens it.

Pain Management

Pancreatic cancer can cause significant pain, classically a deep, gnawing ache in the upper abdomen radiating to the back. Pain should be treated early and seriously.

You do not have to “tough it out” — effective pain control is available and improves everything. Untreated pain wears down sleep, appetite, mood, and the strength needed for treatment, so controlling it is not a luxury — it is part of staying well enough to fight the cancer. There is a full toolbox. Medications range from non-opioids to opioids, and when opioids are needed they are used appropriately and safely under your team’s guidance; fears of addiction should not prevent adequate pain relief in this setting. For the characteristic deep back/abdominal pain, a specific and often highly effective procedure called a celiac plexus block (or neurolysis) — an injection that quiets the nerves carrying pain signals from the pancreas — can substantially reduce pain and the need for opioids, and can be done endoscopically or through the skin. Radiation is sometimes used to relieve pain from a specific area. Treating constipation (a near-universal side effect of opioids), nerve pain, and the emotional component of pain all matter too. The key message: tell your team about pain early and specifically — where it is, how bad (a 0–10 scale helps), what makes it better or worse — and ask for a referral to palliative care, a specialty devoted to symptom relief and quality of life that, studied in cancer, can improve both how people feel and sometimes how long they live. Palliative care works alongside cancer treatment from the start; it is not the same as hospice and does not mean giving up.

Medications. Treatment starts with non-opioid options where appropriate and escalates to opioids as needed. Opioids are appropriate in cancer pain — fear of them should not stand in the way of comfort. A bowel regimen is given alongside to prevent constipation.
Celiac plexus neurolysis. A highly effective, guideline-endorsed procedure that directly interrupts pain nerves. Using endoscopic ultrasound or CT guidance, a specialist injects a numbing agent and then alcohol into the celiac plexus. Relief commonly lasts 3–6 months and the procedure can be repeated. Ask the team early, rather than after months of difficult pain.
Radiation for pain. Focused radiation can relieve pain from a specific tumor site or bone metastases.
Complementary approaches. Acupuncture, massage, gentle movement, and mindfulness can complement medical pain control. They are additions, not replacements.

A tumor in the head of the pancreas often presses on the bile duct, causing jaundice. This is relieved by placing a stent through an endoscopic procedure (ERCP). For a patient facing months of chemotherapy, a self-expanding metal stent is generally preferred over plastic (it lasts longer).

Urgent signs after a stent: Fever or chills, worsening or returning jaundice, dark urine, new confusion, or right upper abdomen pain can mean the stent is blocked or infected (cholangitis) — this is an emergency. Seek immediate care.

Pancreatic cancer carries one of the highest risks of blood clots of any cancer. New leg swelling, sudden shortness of breath, or chest pain should prompt urgent medical attention.

Call the oncology team or go to urgent care for:

Fever ≥ 100.4°F during chemotherapy
Fever, chills, worsening jaundice after a biliary stent
Sudden shortness of breath, chest pain, or leg swelling/pain
Persistent vomiting or inability to keep fluids down
Severe diarrhea, black/bloody stools, or heavy bleeding
Severe, new, or rapidly worsening abdominal or back pain
Signs of blood-sugar emergency (confusion, shakiness, fainting)

If the Cancer Returns or Progresses

Most pancreatic cancers, even those treated with the best modern care, will at some point progress or recur. This section is about what happens then. It is hard to read, and you may wish to come back to it later. But knowing the shape of what may come makes it less frightening and allows decisions to be made with a clear head.

The cancer can evolve under treatment, and a fresh biopsy or liquid biopsy at progression sometimes reveals a new targetable alteration. If full molecular profiling was never done, progression makes it essential. If it was done at diagnosis, ask whether repeating it now could open an option.

The next line is generally chosen so that it does not rely on the same drugs that just failed:

If started on FOLFIRINOX-type → a gemcitabine-based regimen is a common second line.
If started on gemcitabine + nab-paclitaxel → a fluorouracil-based regimen (e.g., liposomal irinotecan with fluorouracil, per the NAPOLI-1 (NCT01494506) trial).

Performance status drives the decision. Each successive line tends to produce a smaller, shorter benefit. A patient who is still strong may reasonably try further lines. A patient who has become frail may receive more benefit from excellent symptom control than from further chemotherapy. This is an honest, individual conversation.

There may come a point when further treatment aimed at the cancer itself is more likely to cause harm than benefit. Reaching that point is not a failure. It is a change in the goal of care — from controlling the cancer to making sure the patient lives as well and as comfortably as possible. Hospice care is built for exactly this, and patients who enter hospice often live as long as or longer than expected, with better quality of life.

Decision trigger: If a chemotherapy regimen is no longer controlling the cancer, that is the moment to deliberately pause and reassess: Is the patient well enough for more chemotherapy? Has the tumor been fully and recently profiled? Is there a clinical trial? Would a second opinion open an option? And what does the patient actually want the next months to look like?

Emerging Local Therapies

For patients whose pancreatic cancer is locally advanced (cannot be surgically removed but has not spread to distant organs), several local treatment approaches are under active investigation. These are not standard of care but represent areas of genuine research interest.

Irreversible electroporation (IRE), marketed as NanoKnife, is a non-thermal ablation technique that uses short, high-voltage electrical pulses to create permanent pores in cell membranes, causing cell death. Unlike heat-based ablation, it preserves nearby blood vessels and bile ducts, making it potentially suitable for pancreatic tumors that encase major vessels.

The PANFIRE-2 trial was a Phase II, multicenter, prospective, single-arm study conducted in the Netherlands. It enrolled 50 patients: 40 with locally advanced pancreatic cancer and 10 with local recurrence after prior surgery.

Key results:

Median overall survival from diagnosis: 17 months (95% CI: 15–19)
Median overall survival from the IRE procedure: 10 months (95% CI: 8–11)

Published in Radiology 2020 (PubMed 31687922).

Important limitations. PANFIRE-2 was a single-arm study with no randomized comparison group. Without a control arm, it is impossible to determine how much of the observed survival is attributable to IRE versus patient selection or concurrent chemotherapy. The procedure carries risks including pancreatitis, bile leak, and vascular complications. IRE for pancreatic cancer is not FDA-approved for this indication and remains investigational. It is available only at a small number of specialized centers. Discuss with your oncology team whether participation in an IRE trial is appropriate for your situation.

class="content-section" data-stage="progression">

Clinical Trials: How to Find Them

Clinical trials are not a last resort. Every meaningful improvement in this disease was established through a trial. For some patients, a well-matched trial is the best available treatment.

Why trials matter especially now — the KRAS story. Almost all pancreatic cancers (around 9 in 10) are driven by a change in a gene called KRAS, which for decades was considered impossible to target with medicines. That is finally changing, and it is one of the most hopeful developments in this disease in a generation. A new oral drug, daraxonrasib, is designed to block the mutated RAS protein across the common forms found in pancreatic cancer; in a large phase 3 trial in people whose cancer had already been treated, it roughly doubled survival compared with standard chemotherapy. It is still investigational (not yet FDA-approved) and available through trials and an expanded-access program, and other KRAS-targeting drugs are following close behind. Because these therapies are reached mainly through clinical trials and specialized centers, asking about trials early — and getting your tumor’s genetics tested — can open doors that did not exist even a couple of years ago.

How to actually find a trial. Start by asking your oncologist whether a trial fits your situation, and request referral to a high-volume pancreatic cancer center, where most trials run. Make sure germline (inherited) and tumor (somatic) genetic testing has been done, because results — BRCA or PALB2, MSI-high status, NTRK or NRG1 fusions, and your specific KRAS variant — determine which targeted trials and treatments you may qualify for. Free matching services can help: the Pancreatic Cancer Action Network (PanCAN) offers personalized clinical-trial matching and patient services, and ClinicalTrials.gov lists trials you can search by location. Asking about a trial commits you to nothing; it simply tells you what options exist. The best time to explore trials is before you need them — ideally early, while you are strongest and have the most options.

A trial is a carefully designed research study testing a treatment under close supervision. It is governed by strict ethical rules. A patient can leave at any time. In cancer trials, patients are essentially never given a placebo instead of treatment — the comparison group receives the current standard treatment.

Phase	What it tests
Phase 1	Primarily safety and dosing; access to newest approaches.
Phase 2	Whether the treatment shows enough activity to warrant a larger trial.
Phase 3	Head-to-head comparison against the current standard in many patients.

The match between the trial and the tumor matters more than the phase number.

Precision Promise. A large, adaptive platform trial sponsored by PanCAN, run at major centers including Huntsman. Tests several experimental regimens at once against the standard of care.
RAS-targeted therapy trials. Daraxonrasib, zoldonrasib, and others in previously treated and increasingly first-line settings. Because most pancreatic cancers are RAS-driven, most patients are biologically eligible.
Neoadjuvant/perioperative trials for resectable and borderline resectable disease.
Trials for specific molecular subsets — PARP inhibitor combinations for BRCA/PALB2, immunotherapy approaches, drugs for rare fusions.
mRNA cancer vaccine trials — early promise in small studies, now being tested more broadly.

Ask the treating oncologist directly: “Given this patient’s stage and molecular profile, what trials are open here and elsewhere?”
PanCAN Patient Services (1-877-272-6226) — free, personalized Clinical Trial Finder staffed by case managers.
ClinicalTrials.gov — the U.S. government registry. Search “pancreatic cancer” and filter by “recruiting” and location.
Contact a major center directly. Many offer remote record review.
NCI Cancer Information Service (1-800-422-6237).

If a patient cannot join a trial but a promising investigational drug exists, an expanded-access program may allow access outside a trial. The FDA permitted such a program for daraxonrasib in May 2026 for eligible patients with previously treated metastatic pancreatic cancer. The oncology team initiates this process — a patient cannot apply directly.

The high-yield habit: Ask about clinical trials at three moments, every time: at diagnosis, before starting each new line of treatment, and at every progression. Trials are not what you turn to when standard options run out — by then, eligibility for the best trials may have passed.

class="content-section" data-stage="progression">

A Directory of Major Pancreatic Cancer Centers

For a disease where surgery is technically demanding and treatment is complex, where care is delivered measurably changes outcomes.

Huntsman Cancer Institute — University of Utah Health
2000 Circle of Hope Drive, Salt Lake City, Utah 84112
Main: 801-587-7000 | New patient: 1-888-424-2100

The only NCI-designated Comprehensive Cancer Center in the Mountain West, serving Utah, Idaho, Wyoming, Montana, and Nevada. Dedicated multidisciplinary GI oncology program with high-volume pancreatic surgery, active clinical trials portfolio including platform trials and RAS-targeted drug research, and a High-Risk Pancreatic Cancer Clinic for people with inherited risk.

Center	Location	Contact
Johns Hopkins — Sol Goldman Pancreatic Cancer Research Center	Baltimore, MD	410-955-5222
Mayo Clinic	Rochester, MN (also AZ & FL)	507-538-3270
MD Anderson Cancer Center	Houston, TX	1-877-632-6789
Memorial Sloan Kettering	New York, NY	1-800-525-2225
UCSF — Helen Diller Family Comprehensive Cancer Center	San Francisco, CA	1-877-887-7184
Dana-Farber / Mass General	Boston, MA	1-877-442-3324
Mayo Clinic Arizona	Phoenix / Scottsdale, AZ	480-301-8000
Cedars-Sinai	Los Angeles, CA	1-800-233-2771
City of Hope	Duarte, CA	1-800-826-4673
UPMC Hillman Cancer Center	Pittsburgh, PA	412-647-2811

Most major centers offer remote second-opinion services: records can be sent anywhere, and geography need not limit a second opinion. A patient does not need to be wealthy or well-connected to be seen — these centers see patients with ordinary insurance, including Medicare and Medicaid.

International Options

The major guidelines (NCCN, ESMO, Japanese Pancreas Society) agree on the fundamentals: surgery at a specialized center, combination chemotherapy, universal molecular testing, and integrated supportive care. A patient receiving guideline-directed care in the U.S. is receiving care consistent with the international standard.

Minor differences exist — for example, the oral drug S-1 is widely used in Japan after surgery but is not routinely used in the U.S. due to differences in drug metabolism between populations. See the International Adjuvant Research section for detailed JASPAC-01 trial data.

Some clinics market unproven treatments to international patients at very high out-of-pocket cost, often with persuasive testimonials. Warning signs: treatments not available through normal medical channels, large upfront payments, claims that sound far better than the medical literature supports, and discouragement of standard care. An international trip during the aggressive early phase of pancreatic cancer also consumes time, money, and energy, and carries risks of blood clots and infection during travel. Before sending money or traveling, review any such option with the patient’s oncologist.

Supporting the Patient & the Family

A pancreatic cancer diagnosis lands on a whole family, not only on the patient.

Fear, anger, grief, numbness, and moments of unexpected normalcy can all occur, sometimes within the same hour. There is no correct way to feel. Clinical depression and anxiety are common and treatable — not a weakness or a failure of attitude. If the patient is persistently unable to sleep, has lost interest in everything, or feels hopeless, tell the oncology team. Most cancer centers have psycho-oncology services.

Accept and assign help. When people ask what they can do, have a specific list of meals, rides, errands, or childcare.
Protect the caregiver’s own health. Sleep, medical appointments, and brief breaks are not luxuries.
Share the role if possible. A second family member attending appointments or handling insurance relieves enormous pressure.
Use the cancer center’s social worker. Among the most underused resources in cancer care. Generally free.

Addressing these matters early, while there is time and energy, is a gift to the family:

Advance directive / living will — the patient’s wishes for care if they cannot speak for themselves.
Health care power of attorney — naming the medical decision-maker.
Financial power of attorney and a current will or trust.
A practical information list — accounts, passwords, insurance policies, key contacts in one place.

What Family Members Should Know About Their Own Risk

A pancreatic cancer diagnosis naturally raises worry among relatives. The honest, reassuring framing is that most family members do not need to do anything beyond the general healthy-lifestyle advice that applies to everyone — but a specific minority do, and identifying them is genuinely valuable because surveillance can catch disease earlier in those at high inherited risk. The single most useful step is for the person with the cancer to have germline genetic testing. Its result is what tells relatives whether their own risk is meaningfully elevated. If an inherited mutation is found, relatives can be tested for that specific change (“cascade testing”), and those who carry it can enter a surveillance program; those who do not are usually spared further worry. If no inherited mutation is found and there is no strong family pattern, most relatives need no special pancreatic screening. Lifestyle steps that lower risk for everyone — not smoking, maintaining a healthy weight, limiting alcohol, and managing diabetes — are worth reinforcing, but they are not a substitute for genetic counseling where an inherited syndrome or a strong family history is present.

The reassuring part: Most relatives of a pancreatic cancer patient do not need pancreatic screening simply because one family member was diagnosed. A single case with no inherited mutation and no strong family pattern usually does not raise a relative’s risk enough to warrant screening.

The part that requires action: If the patient is found to carry an inherited mutation (BRCA1, BRCA2, PALB2, ATM, CDKN2A, Lynch syndrome), then first-degree relatives should be offered cascade genetic testing. Each first-degree relative has roughly a one-in-two chance of carrying it. A relative who tests positive can be enrolled in a high-risk surveillance program. A relative who tests negative is typically spared further concern.

For high-risk relatives, surveillance typically involves annual imaging (MRI with MRCP or endoscopic ultrasound), often beginning around age 50. Huntsman Cancer Institute runs a High-Risk Pancreatic Cancer Clinic for this purpose.

An Honest Conversation About Hope

Pancreatic cancer has a fearsome reputation, and it would be dishonest to pretend otherwise — it remains one of the hardest cancers to treat. But two things are true at once, and holding both is what realistic hope looks like. First, the statistics you may have read are averages drawn from large groups and from the past; they cannot tell you what will happen to you, and they do not reflect the most recent advances. Outcomes vary widely: some people live far longer than the averages, particularly when the cancer is found earlier, when it can be removed surgically, and when care is delivered at an experienced center. Second, the ground is genuinely shifting — new chemotherapy combinations, the first medicines aimed at the KRAS driver behind most pancreatic cancers, maintenance therapy for people with inherited BRCA mutations, and a deeper understanding of the disease are all translating into real, if hard-won, progress.

Hope here is not about denying the seriousness of the diagnosis; it is about directing your energy where it makes a difference. The most powerful steps are concrete: get care at a high-volume pancreatic center (and a second opinion), have genetic testing done, ask about clinical trials early, protect your nutrition and strength, treat pain and symptoms aggressively, and involve palliative care for quality of life from the start. Equally, hope includes living well — tending to relationships, meaning, and the things that matter to you — whatever the course of the disease. Many people find that focusing on what they can influence, leaning on their care team and loved ones, and taking the illness one decision at a time restores a sense of agency. You are not a statistic, and you do not face this alone.

Five-year survival statistics describe the past, not the present. They reflect patients treated years ago and do not yet capture modern combination chemotherapy, universal molecular testing, or the RAS-targeted drugs now moving through trials. A patient treated today is not bound by yesterday’s numbers.

What hope can honestly rest on:

Hope that this patient is one who does better than the average — because someone is, and the factors in this guide tilt the odds.
Hope grounded in action: getting to a high-volume center, completing molecular testing, finding the right trial.
Hope for good time — months and years lived with meaning, with symptoms controlled, whatever the eventual outcome.
Hope from the pace of progress. Pancreatic cancer research is moving faster now than at any point in its history.

The Most Important Priorities, Ranked

If this guide were compressed into a single page, it would be this one.

Get to a high-volume specialized center now — especially before any surgery.
Confirm the stage and resectability with expert review.
Order germline genetic testing and full tumor molecular profiling immediately.
Start guideline-directed standard treatment without unnecessary delay.
Ask about clinical trials — now, and at every decision point.
Get nutrition and enzyme support in place early.
Bring in palliative and supportive care early — alongside treatment, not instead of it.
Build the support system — for the patient and the caregiver.
Put practical and legal documents in order.
Take care of the relationships and the time.

If you can only do three things this week:
1. Call a high-volume center (for Utah/Mountain West: Huntsman, 1-888-424-2100).
2. Make sure germline testing and tumor profiling have been ordered.
3. Call PanCAN Patient Services at 1-877-272-6226 for free, personalized help.

Questions to Ask the Medical Team

Bring these to appointments. No one will ask all of them, and not all apply. Choose the ones that fit.

What is the exact stage and resectability category?
Has a pancreas-protocol CT been done and reviewed by a specialized team?
Have germline genetic testing and full tumor molecular profiling been ordered?
Should we get a second opinion at a high-volume center?
Are there clinical trials that fit this situation?
Is the tumor mismatch-repair-deficient (MSI-high)?
What is the CA19-9 baseline, and does it apply to this patient?

How many pancreatic operations does this hospital and this surgeon perform per year?
What is the expected surgical mortality rate here?
Can tumor tissue be snap-frozen and banked for future testing or organoid generation?
What are the recovery milestones before adjuvant chemotherapy can begin?

Which chemotherapy regimen is recommended and why?
What are the expected side effects, and what support is available?
Has the molecular profile been reviewed against all available targeted therapies and trials?
Is this patient eligible for a RAS-targeted trial or expanded-access program?
Should the patient be on PERT, and is the dose adequate?
Can we have a palliative care referral from the start?

Should the tumor be re-profiled?
Is the patient well enough for more chemotherapy, honestly?
What trials are available now?
Would a second opinion at a major center open an option?
At what point should we discuss comfort-focused care?

Decision Triggers & a Realistic Timeline

If this happens	Then do this
Diagnosis is made	Confirm pancreas-protocol imaging and high-volume review; order germline and tumor molecular testing.
Surgery recommended at a low-volume hospital	Get a second opinion at a high-volume center before the operation.
Patient is jaundiced	Ask about biliary drainage; metal stent preferred for long chemo courses.
Weight loss, bloating, or greasy stools	Ask about starting PERT and request a dietitian referral.
Significant pain	Ask about celiac plexus neurolysis early.
Fever/chills/worsening jaundice after a stent	Seek urgent care — possible cholangitis.
Side effects becoming hard to tolerate	Report promptly; doses can usually be adjusted without losing the benefit.
CA19-9 rising or scan looks worse	Confirm true progression with the team; reassess the whole plan including trials.
BRCA-mutated disease stable on platinum ~4 months	Discuss switching to olaparib maintenance.
Standard chemo no longer controlling disease	Pause and reassess: re-profile tumor, screen for trials, weigh next line honestly.

Weeks 1–4: Diagnosis confirmed, staging completed, molecular testing sent, bile duct relieved if needed, nutrition support started, treatment plan set, treatment begun.
Months 1–6: Active treatment. Scans and CA19-9 monitored every 2–3 months. Supportive care managed actively. Trial options revisited.
Months 6–12: For resected patients, surveillance every 3–6 months. For advanced disease, maintenance therapy or next-line planning.
Throughout: Supportive care, attention to the caregiver, practical/legal preparations, and protected time for relationships.

Financial & Practical Resources

Oncology social worker — available at essentially every cancer center, generally at no cost. Experts in navigating insurance, finding assistance programs, and emotional support. Ask for an introduction at the first or second visit.
Hospital financial counselor — helps with billing, payment plans, and charity-care applications.
Patient navigator — helps coordinate appointments and connect to services.

Pancreatic Cancer Action Network (PanCAN) — 1-877-272-6226, pancan.org. Free Patient Services including trial matching, molecular profiling (Know Your Tumor), dietitian consultations.
Lustgarten Foundation — lustgarten.org. Research funding and patient resources.
Let’s Win Pancreatic Cancer — letswinpc.org. Curated source on science and trials.
National Pancreas Foundation — pancreasfoundation.org. Patient resources and designated centers.
Hirshberg Foundation — pancreatic.org. Patient resources and financial assistance for qualifying patients.

Resource	What it offers	Contact
CancerCare	Free counseling, support groups, limited financial assistance	1-800-813-4673 / cancercare.org
American Cancer Society	Support programs, Hope Lodge lodging, transportation	1-800-227-2345 / cancer.org
Patient Advocate Foundation	Insurance navigation, medical debt help	1-800-532-5274 / patientadvocate.org
HealthWell / PAN Foundation	Copayment and premium assistance	healthwellfoundation.org / panfoundation.org

Insurance tip: A denial is not the end — it is the start of an appeal. The oncology team can supply letters of medical necessity. Pancreatic cancer is included in the Social Security Administration’s Compassionate Allowances program for expedited disability decisions.

The Path to a Personalized Analysis

Gathering these into one binder or folder is the single most useful organizing task a family can do:

The exact diagnosis — full pathology report including type, grade, and features.
Stage and resectability category — and, if metastatic, where the disease has spread.
The imaging — pancreas-protocol CT/MRI, ideally reviewed by a high-volume center.
Pathology/surgical details — margin status (R0/R1), lymph nodes examined, tumor size.
Molecular and germline results — KRAS status/subtype, BRCA/PALB2/ATM, mismatch-repair, rare fusions.
CA19-9 trend — baseline and changes.
Treatment history — what has been given, with what response and side effects.
General health — age, other conditions, weight change, performance status.

With these in hand, the team can move from the general to the specific: confirm the right regimen, identify targeted therapies and trials, and build a concrete next-step plan.

Pregnancy and Pancreatic Cancer

Pancreatic cancer during pregnancy is very rare, because it is mostly diagnosed after age 60. When it does happen, care is coordinated between oncology and maternal-fetal medicine, and decisions depend on how far along the pregnancy is and how advanced the cancer is.

Key safety points

The chemotherapy drugs used in pancreatic cancer (oxaliplatin, irinotecan, 5-fluorouracil, gemcitabine, nab-paclitaxel) can harm a developing baby, especially in the first trimester. Reliable contraception is advised during treatment for anyone who could become pregnant.
Olaparib (Lynparza) carries a specific warning about harm to a developing baby and is not used in pregnancy; contraception is required during treatment and for some months afterward.
Tell your whole team early if you are pregnant, might be, or are planning a pregnancy — before any scan, medicine, or radiation is started.

Failed & De-Adopted Therapies

Knowing what has been tried and did not work is important. The history of pancreatic cancer treatment includes many approaches that seemed promising in the laboratory or in early trials but ultimately failed to help patients in rigorous testing. Understanding these failures prevents wasted time, protects patients from ineffective treatments, and explains why the current standard regimens are what they are.

What it was: Erlotinib is an oral EGFR (epidermal growth factor receptor) inhibitor. The PA.3 trial tested erlotinib added to gemcitabine versus gemcitabine alone in advanced pancreatic cancer.

What happened: The combination was technically statistically significant but provided only a 10-day improvement in median overall survival (6.24 vs. 5.91 months). While FDA-approved for this indication, the clinical benefit was so marginal that most oncologists and guidelines no longer recommend it. The rash that predicted benefit was present in only a small subset of patients.

Why it matters: Erlotinib in pancreatic cancer became a cautionary example of statistical significance without meaningful clinical benefit. Modern guidelines have effectively de-adopted this combination in favor of multi-drug regimens with larger survival gains.

What they were: Drugs such as vismodegib and saridegib that targeted the hedgehog signaling pathway, aiming to dissolve the dense stroma surrounding pancreatic tumors so chemotherapy could reach the cancer cells.

What happened: Despite dramatic results in mouse models, clinical trials in patients were negative. The phase 2 trial of vismodegib with gemcitabine (NCT01064622) showed no improvement in outcomes. Saridegib trials were stopped early. Researchers discovered that the stroma, while it blocks drugs, also physically restrains the cancer — removing it allowed the tumor to spread more aggressively.

Why it matters: This taught the field that the pancreatic stroma is not simply a barrier to be destroyed. Modern approaches now aim to modify the stroma rather than eliminate it.

What it was: Bevacizumab is an anti-VEGF antibody that blocks blood vessel growth to tumors. It works in colon cancer, lung cancer, and several other tumor types.

What happened: The CALGB 80303 trial tested bevacizumab added to gemcitabine in metastatic pancreatic cancer. Despite strong rationale and a large randomized trial, there was no survival benefit (5.8 vs. 5.9 months). Additional trials combining bevacizumab with other regimens were also negative.

Why it matters: Pancreatic tumors have an unusual blood supply already compressed by the stroma. Anti-angiogenic strategies that work in other cancers do not work in PDAC, reinforcing how fundamentally different this tumor biology is.

What it was: PD-1 and PD-L1 checkpoint inhibitors (e.g., pembrolizumab, nivolumab, durvalumab) have transformed treatment for melanoma, lung cancer, and other tumor types.

What happened: Multiple trials testing these drugs in unselected (microsatellite-stable) pancreatic cancer have failed. Single-agent checkpoint inhibitors showed response rates below 3% in MSS PDAC. Combinations of checkpoint inhibitors with chemotherapy (e.g., durvalumab + gemcitabine/nab-paclitaxel in CCTG PA.7) also showed no benefit.

Why it matters: The dense, immune-suppressive stroma of PDAC actively excludes and disables immune cells, rendering standard immunotherapy ineffective for the ~98% of patients with microsatellite-stable tumors. The rare exception — MSI-high/dMMR tumors (~1–2%) — does respond, which is why testing for this marker remains critical.

What it was: Removing a much larger number of lymph nodes during a Whipple procedure, on the theory that more aggressive surgery would catch more cancer spread.

What happened: Multiple randomized controlled trials showed that extended lymph node removal does not improve survival compared with standard lymphadenectomy, and it increases surgical complications including diarrhea and delayed recovery.

Why it matters: Standard lymphadenectomy (aiming for at least 15 lymph nodes examined for adequate staging) is now the accepted approach. More aggressive surgery is not better surgery in this disease.

What it was: Adding radiation therapy as a routine part of treatment after pancreatic cancer surgery, on top of chemotherapy.

What happened: The ESPAC-1 trial showed that adjuvant chemoradiation was actually detrimental compared with chemotherapy alone. The more recent RTOG 0848 trial confirmed that adding radiation to adjuvant chemotherapy does not improve overall survival (28.1 vs. 27.2 months). European guidelines now recommend against routine adjuvant chemoradiation.

Why it matters: Routine chemoradiation after surgery for pancreatic cancer has been largely de-adopted. Radiation may still have selective roles (positive surgical margins, locally advanced disease), but it is no longer a default part of the treatment plan after complete surgical removal.

Why this list matters. These failures are not signs that research is failing — they are evidence that the scientific process is working. Each negative trial taught researchers something important about pancreatic cancer biology. The current standard treatments (FOLFIRINOX, gemcitabine/nab-paclitaxel, NALIRIFOX) and the promising new RAS-targeted approaches exist because of what was learned from these failures. A treatment’s absence from guidelines usually means it was tested and found wanting, not that it was overlooked.

Treatments Deliberately Not Recommended

Honesty requires explaining what was left out and why.

Laetrile (amygdalin). Tested and found ineffective; carries a risk of cyanide poisoning.
The Gonzalez regimen (supplements, enzymes as cancer treatment, coffee enemas). Tested specifically in pancreatic cancer by the NIH: patients on the regimen did worse and lived shorter lives than those on standard chemotherapy. (Note: this is entirely separate from prescription PERT for digestion, which is genuinely beneficial.)
High-dose intravenous vitamin C. Despite decades of interest, not shown in rigorous trials to extend survival. Being studied in some legitimate trials as an addition to chemotherapy; outside a trial, should not substitute for proven treatment.
Antineoplastons. No reliable independent evidence; never gained guideline acceptance.
Extreme or restrictive diets, fasting protocols. The central nutritional threat in pancreatic cancer is wasting. Diets that restrict calories accelerate that wasting, weaken the patient, and reduce the ability to tolerate chemotherapy.

The one rule that matters most: Tell the oncology team about every supplement, product, diet, or alternative treatment under consideration — including the ones that seem harmless. Some supplements change how chemotherapy is processed, raise bleeding risk, or interfere with treatment. The team is not there to forbid; they are there to keep the patient safe. Secrecy is the real danger. Disclosure is the rule.

Glossary of Terms

Adenocarcinoma: A cancer beginning in gland-like cells. PDAC is the most common type of pancreatic cancer.
Adjuvant therapy: Chemotherapy given after surgery to destroy remaining microscopic cancer cells.
Borderline resectable: A tumor touching nearby major blood vessels, making complete surgical removal uncertain.
CA19-9: A blood protein many pancreatic cancers produce; used for tracking disease, never alone.
Cachexia: A syndrome of progressive weight loss and muscle wasting driven by the tumor; not reversible by food alone.
Celiac plexus neurolysis: A procedure that injects alcohol into pain-carrying nerves behind the pancreas; can reduce pain and opioid use.
Desmoplastic stroma: The dense fibrous tissue pancreatic tumors build around themselves, blocking drug delivery.
dMMR / MSI-high: A DNA-repair defect, uncommon in PDAC, that makes tumors responsive to immunotherapy.
EPI (Exocrine Pancreatic Insufficiency): Shortage of digestive enzymes causing malabsorption and weight loss; treated with PERT.
FOLFIRINOX: A four-drug chemotherapy combination (fluorouracil, leucovorin, irinotecan, oxaliplatin).
Germline testing: Testing for inherited gene mutations (blood/saliva); recommended for every pancreatic cancer patient.
KRAS: A gene mutated in 85–90% of pancreatic cancers. New RAS-targeted drugs are in advanced trials.
Liquid biopsy: A blood test detecting tumor DNA fragments; useful when tissue is limited.
Maintenance therapy: A gentler treatment to hold disease in check (e.g., olaparib for BRCA-mutated tumors).
Margins (R0 / R1): R0 = no cancer at the surgical edge (clear); R1 = microscopic cancer reaches the edge.
Neoadjuvant therapy: Chemotherapy given before surgery to shrink the tumor and treat microscopic spread.
Olaparib: A PARP-inhibitor pill for maintenance in metastatic PDAC with an inherited BRCA mutation.
Palliative care: Specialized symptom-relief care given alongside treatment at any stage. Not the same as hospice.
PERT: Pancreatic enzyme replacement therapy — prescription enzyme capsules taken with meals.
SBRT: Stereotactic body radiation therapy — precise, high-dose radiation in a few sessions.
Type 3c diabetes: Diabetes caused by damage to or removal of the pancreas. Both insulin and glucagon are lost, making blood sugar unstable.
Whipple procedure: Surgery removing the pancreatic head, duodenum, gallbladder, and part of the bile duct. The most common pancreatic cancer operation.

Sources & Key Trials

Guidelines:

NCCN Clinical Practice Guidelines — Pancreatic Adenocarcinoma (Version 2.2026)
ESMO Clinical Practice Guidelines for pancreatic cancer
ASCO Guidelines on metastatic pancreatic cancer management and germline testing

Landmark trials:

Trial	What it established
PRODIGE 24	mFOLFIRINOX as adjuvant chemo after surgery substantially improved survival over gemcitabine.
PRODIGE 4 / ACCORD 11	FOLFIRINOX improved survival over gemcitabine in metastatic disease.
MPACT (NCT00844649)	Gemcitabine + nab-paclitaxel improved survival over gemcitabine alone in metastatic disease.
NAPOLI-3	NALIRIFOX improved survival over gem+nab-paclitaxel as first-line for metastatic disease.
NAPOLI-1	Liposomal irinotecan + fluorouracil improved survival after prior gemcitabine-based treatment.
ESPAC-4	Gemcitabine + capecitabine improved adjuvant outcomes.
CONKO-001	Established adjuvant gemcitabine as beneficial after surgery.
PREOPANC / PREOPANC-2	Established neoadjuvant therapy before surgery for resectable/borderline disease.
POLO	Olaparib maintenance improved PFS in metastatic disease with inherited BRCA mutation.
CodeBreaK 100	Activity of KRAS G12C inhibitor sotorasib in previously treated G12C-mutated PDAC.
RASolute 302	Daraxonrasib roughly doubled median OS in previously treated metastatic disease (13.2 vs. 6.7 months). Still investigational as of mid-2026.
JASPAC-01	Phase 3 RCT (385 patients). Adjuvant S-1 was superior to gemcitabine after resection in Japan. 2-year OS: 70% vs. 53%; HR 0.57 (p<0.0001). Lancet 2016. PubMed 27265347
PANFIRE-2	Phase II single-arm study (50 patients). Irreversible electroporation (NanoKnife) for locally advanced PDAC. Median OS from diagnosis: 17 months. Radiology 2020. PubMed 31687922

Reliable organizations: PanCAN (pancan.org, 1-877-272-6226), NCI (cancer.gov, 1-800-422-6237), Lustgarten Foundation (lustgarten.org), Let’s Win (letswinpc.org), National Pancreas Foundation (pancreasfoundation.org), Huntsman (huntsmancancer.org, 1-888-424-2100).

What This Guide Does Not Know

It cannot predict what will happen to one person. Statistics describe groups.
It cannot replace examination of the actual patient. The treating team’s in-person judgment is irreplaceable.
Its evidence is current only to late May 2026. The RAS-targeted drug landscape is evolving rapidly.
It is built around ordinary PDAC. If the diagnosis is a neuroendocrine tumor, acinar cell carcinoma, or another uncommon type, the treatment sections do not apply.
It cannot weigh what matters to one particular person. How to balance length of life against quality of life belongs to the patient and the people who love them.

These limits are the reason this guide keeps returning to the same two anchors: get to an expert pancreatic team, and make decisions together with them.

Updated Information

Changes and additions since this guide was first published. Newest updates appear first.

26 May 2026 Trial JASPAC-01 trial data added (S-1 adjuvant therapy) — Phase 3 RCT (385 patients) establishing S-1 as standard adjuvant therapy in Japan. 2-year survival 70% vs. 53%; HR 0.57. Context on Western vs. Japanese standards included. Go to section →
26 May 2026 Trial PANFIRE-2 trial data added (IRE/NanoKnife) — Phase II single-arm study (50 patients) of irreversible electroporation for locally advanced disease. Median OS from diagnosis: 17 months. Limitations of single-arm design noted. Go to section →
21 May 2026 New Guide published — Comprehensive pancreatic cancer research guide covering understanding PDAC, standard treatment, molecular testing, clinical trials, nutrition, supportive care, major centers, and practical resources. Go to top →
21 May 2026 Trial RASolute 302 trial data included — Daraxonrasib (pan-RAS inhibitor) phase 3 results in previously treated metastatic PDAC. Expanded-access program noted. Go to section →
21 May 2026 New Early detection section — High-risk surveillance, warning signs, and honest framing of screening limitations for the general population. Go to section →
21 May 2026 New NALIRIFOX first-line approval — NAPOLI-3 trial data and 2024 FDA approval for first-line metastatic disease included. Go to section →
21 May 2026 New Zenocutuzumab (Bizengri) for NRG1 fusions — FDA accelerated approval for PDAC with NRG1 fusion noted. Go to section →

A Research Guide for
Pancreatic Cancer

⚡ Quick Start — If You Read Nothing Else

Understanding Pancreatic Cancer (PDAC)

Early Detection: What Proactive Testing Can Do

Staging & Resectability

ðŸ”€ Decision Flowchart: Pancreatic Cancer Initial Assessment

The Stroma Problem: Why Drugs Struggle to Reach the Tumor

Evaluating Treatment Claims

The Phases of Treatment

Standard Treatment Foundation

Choosing a Treatment Center

The First Weeks: A Concrete Action Checklist

Tissue, Biopsies & What Can Be Tested

The Molecular & Genetic Decision Tree

International Adjuvant Research

Nutrition, Digestion, Weight & Blood Sugar

Supportive Care That Changes Outcomes

Pain Management

If the Cancer Returns or Progresses

Emerging Local Therapies

Clinical Trials: How to Find Them

A Directory of Major Pancreatic Cancer Centers

International Options

Supporting the Patient & the Family

What Family Members Should Know About Their Own Risk

An Honest Conversation About Hope

The Most Important Priorities, Ranked

Questions to Ask the Medical Team

Decision Triggers & a Realistic Timeline

Financial & Practical Resources

The Path to a Personalized Analysis

Pregnancy and Pancreatic Cancer

Failed & De-Adopted Therapies

Treatments Deliberately Not Recommended

Glossary of Terms

Sources & Key Trials

What This Guide Does Not Know

Updated Information

Important Drug Safety Information

A Research Guide forPancreatic Cancer

⚡ Quick Start — If You Read Nothing Else

Understanding Pancreatic Cancer (PDAC)

Early Detection: What Proactive Testing Can Do

Staging & Resectability

ðŸ”€ Decision Flowchart: Pancreatic Cancer Initial Assessment

The Stroma Problem: Why Drugs Struggle to Reach the Tumor

Evaluating Treatment Claims

The Phases of Treatment

Standard Treatment Foundation

Choosing a Treatment Center

The First Weeks: A Concrete Action Checklist

Tissue, Biopsies & What Can Be Tested

The Molecular & Genetic Decision Tree

International Adjuvant Research

Nutrition, Digestion, Weight & Blood Sugar

Supportive Care That Changes Outcomes

Pain Management

If the Cancer Returns or Progresses

Emerging Local Therapies

Clinical Trials: How to Find Them

A Directory of Major Pancreatic Cancer Centers

International Options

Supporting the Patient & the Family

What Family Members Should Know About Their Own Risk

An Honest Conversation About Hope

The Most Important Priorities, Ranked

Questions to Ask the Medical Team

Decision Triggers & a Realistic Timeline

Financial & Practical Resources

The Path to a Personalized Analysis

Pregnancy and Pancreatic Cancer

Failed & De-Adopted Therapies

Treatments Deliberately Not Recommended

Glossary of Terms

Sources & Key Trials

What This Guide Does Not Know

Updated Information

Important Drug Safety Information

A Research Guide for
Pancreatic Cancer